Therefore, liquid biopsy-based gene detection successfully determines rare gene fusion in clinical assistant diagnoses, such as LOC399815-ALK fusion, which guide efficient and accurate treatment and thereby improving the quality of life for NSCLC patients.[14]. This evidence concerns the gene ALK and non-small cell lung carcinoma.